Stock Market Reviews

Read and share opinions on RZLT (Rezolute, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

Latest News

• All You Need to Know About Rezolute (RZLT) Rating Upgrade to Buy
  Nov 12, 2025
• Can Rezolute (RZLT) Climb 49.4% to Reach the Level Wall Street Analysts Expect?
  Nov 12, 2025
• Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
  Nov 10, 2025
• Rezolute Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update
  Nov 6, 2025
• Rezolute to Host Virtual Investor Event on Ersodetug Development Program
  Nov 5, 2025
• Is Rezolute Inc. (RZLT) One of the Top Long-Term Biotechnology Stocks to Buy
  Oct 29, 2025
• Rezolute to Participate in Upcoming Investor Conferences
  Oct 15, 2025
• Rezolute Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results and Provides Business Update
  Sep 17, 2025
• Rezolute Announces Alignment with FDA on Streamlined Design for Ongoing Phase 3 Trial of Ersodetug in Tumor Hyperinsulinism
  Sep 2, 2025
• Rezolute Appoints Seasoned Commercial Executive Sunil Karnawat as Chief Commercial Officer
  Aug 20, 2025
• Rezolute to Participate in the BTIG Virtual Biotechnology Conference
  Jul 22, 2025
• Rezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of the Endocrine Society (ENDO 2025)
  Jul 9, 2025
• Rezolute Announces Completion of Enrollment in the Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism
  May 28, 2025
• Rezolute, Inc. (RZLT): Analysts See 260% Upside Potential
  May 20, 2025
• Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update
  May 13, 2025
• Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism
  May 5, 2025
• Rezolute, Inc. Announces Closing of Underwritten Offering
  Apr 25, 2025